Compare AbCellera Biologics Inc (ABCL) vs Philip Morris International Inc. (PM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Philip Morris International Inc. — how do they compare? AbCellera Biologics Inc trades at $7.2 (market cap $2.35B), while Philip Morris International Inc. trades at $188.33 (market cap $287.96B). The key difference: Philip Morris International Inc. is far larger — about 122.5× AbCellera Biologics Inc's market cap, and Philip Morris International Inc. pays a 3.18% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | PM | |
|---|---|---|
Market Cap | $2.35B | $287.96B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $191.86 |
52-Week Low | $2.78 | $144.33 |
Enterprise Value | $1.99B | $334.46B |
Dividend Yield | — | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Philip Morris International (PM) trades at $184.76, up 1.37% with strong technical momentum and bullish moving averages. The company reported solid Q1 2026 earnings beat ($1.96 vs $1.86 expected) and maintains robust profitability with 26.74% net income margin. Recent news includes a $500 million impairment charge on Canadian operations and updated 2026 guidance, though IQOS brand recognition remains a positive catalyst.
PM offers stable revenue growth and strong cash flow generation, but faces headwinds from currency volatility and illicit market pressures. Analyst consensus remains bullish with $194.25 price target (68% buy ratings), though recent profit forecast cuts and high debt levels warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
